All lobbying filings
PENN AVENUE PARTNERS
PENN AVENUE PARTNERS filed a Q3 report for ALKERMES, INC. on October 17, 2026, reporting $80,000 in lobbying income.
Lobbying for ALKERMES, INC. · Pharmaceutical manufacturing and biopharmaceutical company.
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 17, 2026
Income
$80,000
What the client paid this registrant for the period.
Client based in
Massachusetts
Lobbyists on this filing
4
-
TIMOTHY FARRELL HANNEGANPreviously held: U.S. General Accounting Office
-
JERR ROSENBAUMPreviously held: Legislative Director, Sen. John Cornyn; Chief of Staff, Rep. Robert Hurt; Chief of Staff, Rep. Jack Kingston; Chief of Staff, Rep. Virgil Goode
-
CHRISTINA MCGARRY DAVIDPreviously held: Legislative Assistant / Scheduler, Rep. Mario Diaz-Balart; Intern, Rep. Doc Hastings
-
JAY SULZMANNPreviously held: Legislative Director/Health Policy Advisor, Sen. Johnny Isakson; Sr. Policy Advisor/LA/LC/SA, Rep. Wally Herger
Government bodies contacted
2
Lobbying activity
1
Regulatory and legislative issues impacting Alkermes. Appropriations. H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Bills named in this filing
1